Effects of ezetimibe on atherosclerosis in preclinical models

Area of Science:

• Pharmacology
• Cardiovascular Research
• Atherosclerosis Research

Background:

• Ezetimibe is a potent inhibitor of sterol absorption, targeting cholesterol uptake in the small intestine.
• Clinical trials indicate ezetimibe's efficacy in reducing atherogenic lipoproteins and achieving lipid level goals.
• Limited direct evidence exists linking ezetimibe-induced lipid improvements to reduced atherosclerosis or cardiovascular events in humans.

Purpose of the Study:

• To evaluate the effect of ezetimibe on atherosclerosis using various animal models.
• To assess ezetimibe's therapeutic potential in preclinical settings relevant to human cardiovascular disease.

Main Methods:

• Ezetimibe's impact on atherosclerosis was examined in ApoE knockout mice, sr-b1(-/-)/apoE(-/-) double knockout mice, and ldlr(-/-)/apoE(-/-) double knockout mice.
• Studies in rabbits investigated ezetimibe's inhibition of diet- and vascular injury-induced atherosclerosis.
• Assessment methods included gross plaque visualization, high-resolution MRI, intima/media thickness, lesion composition, and thrombosis evaluation.

Main Results:

• Ezetimibe consistently and significantly inhibited atherosclerosis in ApoE knockout mice.
• In sr-b1(-/-)/apoE(-/-) mice, ezetimibe significantly reduced aortic sinus plaque, coronary arterial occlusion, myocardial fibrosis, and cardiomegaly.
• Ezetimibe reduced plasma cholesterol and atherosclerosis in ldlr(-/-)/apoE(-/-) mice, independent of functional LDL receptors.
• Studies in rabbits demonstrated ezetimibe's significant inhibition of diet- and vascular injury-induced atherosclerosis.

Conclusions:

• Preclinical evidence consistently shows ezetimibe reduces atherosclerosis in animal models, primarily by decreasing atherogenic lipoproteins.
• Further human outcomes trials are needed to confirm if ezetimibe-mediated lipid reduction translates to reduced atherosclerosis and cardiovascular risk.